CONGRESS ABSTRACT

Background: Heart failure (HF) is a significant global health burden, characterized by high rates of hospitalization and mortality. Recent clinical guidelines emphasize the implementation of "The Four Pillars" of Guideline-Directed Medical Therapy (GDMT) to improve clinical outcomes and quality of life. The primary objective of this study is to evaluate the clinical management and therapeutic adherence within a specialized outpatient Heart Failure Clinic, focusing on the integration of foundational therapies and novel pharmacological agents like Vericiguat (Verquvo). Materials and Methods: This retrospective observational study analyzed a cohort of 400 patients diagnosed with heart failure and followed systematically by a dedicated outpatient HF service. Data collection focused on the prescription rates of the four foundational pillars: Sodium-Glucose Cotransporter-2 inhibitors (SGLT2i), Angiotensin Receptor-Neprilysin Inhibitors (ARNI), Beta-blockers (BB), and Mineralocorticoid Receptor Antagonists (MRA). Furthermore, the usage of the soluble guanylate cyclase (sGC) stimulator, Vericiguat, was assessed. The study also documented specific clinical contraindications that prevented the optimization of these therapies. Results: The analysis revealed a high level of adherence to international guidelines. Approximately 70% of the total cohort received the complete "four pillars" regimen. Specifically, SGLT2 inhibitors (Dapagliflozin or Empagliflozin) were prescribed to 90% of patients, while Beta-blockers and MRAs showed an even higher penetration, exceeding 90% of the population. ARNI therapy was successfully implemented in 60% of cases. Notably, approximately 65% of patients were also treated with Vericiguat, indicating a proactive approach toward high-risk patients. Conclusions: The findings demonstrate that a structured outpatient approach enables high adherence to GDMT, with 70% of patients receiving comprehensive four-pillar therapy. The high utilization of SGLT2i and the integration of Vericiguat suggest an evolving treatment landscape aimed at reducing residual risk. However, clinical challenges such as hypotension and renal dysfunction remain significant hurdles. Dedicated HF clinics are essential for monitoring these parameters, allowing for the maximum possible optimization of life-saving therapies while managing side effects effectively.